Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBX-12 in Advanced or Metastatic Refractory Solid Tumors
NCT04902872Phase 2Completed
- Sponsor
- Cybrexa Therapeutics
- Start
- May 2021
- Primary completion
- Jun 2025
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
A Phase 2 trial of alphalex exatecan in solid tumor, epithelial ovarian cancer (EOC), Small Cell Lung Cancer (SCLC), breast cancer, colorectal cancer (CRC), sponsored by Cybrexa Therapeutics. Started May 2021; status: completed.
02
Drugs
alphalex exatecan
03
Conditions
solid tumorepithelial ovarian cancer (EOC)Small Cell Lung Cancer (SCLC)breast cancercolorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04902872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04902872.